An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia

• Status: Terminated
• Trial end date: 2019-06-04
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and effectiveness of ulocuplumab in combination with low dose cytarabine in the treatment of Newly Diagnosed Acute Myeloid Leukemia (AML).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Antibodies, Monoclonal; Cytarabine

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Newly Diagnosed Acute Myeloid Leukemia (AML)

• Considered inappropriate for intensive remission induction therapy by an investigator

• Not eligible for stem cell transplantation

Exclusion Criteria:

• Acute promyelocytic leukemia

• Current Myelodysplastic syndrome only subjects

• Unstable angina or uncontrolled congestive heart failure

• Any other malignancy, excluding basal or squamous cell carcinoma of the skin, in situ melanoma, cervical carcinoma in situ, localized prostate cancer, or superficial bladder cancer stage 0, from which the subject has not been disease-free for at least 3 years

• Respiratory disease requiring continuous supplemental oxygen

Other protocol defined inclusion/exclusion criteria could apply